| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | paclitaxel | CCLE | pan-cancer | AAC | 0.26 | 3e-09 |
| mRNA | Doxorubicin | gCSI | pan-cancer | AAC | 0.25 | 8e-07 |
| mRNA | BI-2536 | CTRPv2 | pan-cancer | AAC | 0.14 | 4e-06 |
| mRNA | paclitaxel | gCSI | pan-cancer | AAC | 0.21 | 5e-05 |
| mRNA | Irinotecan | CCLE | pan-cancer | AAC | 0.21 | 6e-05 |
| mRNA | docetaxel:tanespimycin (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.13 | 6e-05 |
| mRNA | GSK461364 | CTRPv2 | pan-cancer | AAC | 0.12 | 7e-05 |
| mRNA | Docetaxel | gCSI | pan-cancer | AAC | 0.21 | 8e-05 |
| mRNA | LY-2183240 | CTRPv2 | pan-cancer | AAC | 0.12 | 8e-05 |
| mRNA | GSK1070916 | GDSC1000 | pan-cancer | AAC | 0.12 | 0.0001 |